• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Epirubicin and long-term heart failure risk in breast cancer survivors.

作者信息

Mahmood Syed S, Patel Ravi B, Butler Javed, Vaduganathan Muthiah

机构信息

Division of Cardiology, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY, USA.

Division of Cardiology, Bluhm Cardiovascular Institute at Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

出版信息

Eur J Heart Fail. 2018 Oct;20(10):1454-1456. doi: 10.1002/ejhf.1215. Epub 2018 Jul 4.

DOI:10.1002/ejhf.1215
PMID:29972283
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6179931/
Abstract
摘要

相似文献

1
Epirubicin and long-term heart failure risk in breast cancer survivors.表柔比星与乳腺癌幸存者的长期心力衰竭风险
Eur J Heart Fail. 2018 Oct;20(10):1454-1456. doi: 10.1002/ejhf.1215. Epub 2018 Jul 4.
2
Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial.表阿霉素对乳腺癌女性心力衰竭发生率的长期影响：来自一项随机临床试验的观察。
Eur J Heart Fail. 2018 Oct;20(10):1447-1453. doi: 10.1002/ejhf.1168. Epub 2018 Mar 1.
3
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.表柔比星心脏毒性：469例转移性乳腺癌患者的分析
J Clin Oncol. 1998 Nov;16(11):3502-8. doi: 10.1200/JCO.1998.16.11.3502.
4
New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.表柔比星心脏毒性的新见解：1097例乳腺癌患者的竞争风险分析
J Natl Cancer Inst. 2008 Aug 6;100(15):1058-67. doi: 10.1093/jnci/djn206. Epub 2008 Jul 29.
5
Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.在接受多柔比星或表柔比星化疗治疗癌症的患者中使用右丙亚胺作为心脏保护剂。省级系统治疗疾病部位组。
Cancer Prev Control. 1999 Apr;3(2):145-59.
6
Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer.乳腺癌辅助表柔比星化疗后的长期心脏功能。
Acta Oncol. 2012 Nov;51(8):1054-61. doi: 10.3109/0284186X.2012.702920. Epub 2012 Aug 22.
7
Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.早期乳腺癌患者表柔比星诱导心脏毒性的临床和遗传危险因素
Breast Cancer Res Treat. 2015 Jul;152(1):67-76. doi: 10.1007/s10549-015-3437-9. Epub 2015 May 28.
8
Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.表柔比星与多柔比星的心脏毒性：成本与临床结果。
J Clin Oncol. 2005 Apr 20;23(12):2873; author reply 2873-4. doi: 10.1200/JCO.2005.05.332.
9
Reversible Cardiomyopathy After Epirubicin Administration.表柔比星给药后可逆性心肌病
Int Heart J. 2015;56(4):466-8. doi: 10.1536/ihj.14-416. Epub 2015 Jun 24.
10
Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: results of 5-year follow-up.含表柔比星的大剂量化疗联合自体造血祖细胞输注治疗化疗敏感的转移性乳腺癌患者：5年随访结果
Cancer Chemother Pharmacol. 1999;43(1):8-12. doi: 10.1007/s002800050856.

引用本文的文献

1
Cluster analysis of hotspots and research trends of epirubicin-induced cardiotoxicity: a bibliometric study.表柔比星诱导心脏毒性的热点与研究趋势的聚类分析：一项文献计量学研究
Front Pharmacol. 2025 Aug 20;16:1616162. doi: 10.3389/fphar.2025.1616162. eCollection 2025.
2
Improving cancer patients' prognosis by incorporating mindfulness intervention into the treatment strategy.通过将正念干预纳入治疗策略来改善癌症患者的预后。
World J Psychiatry. 2025 May 19;15(5):102977. doi: 10.5498/wjp.v15.i5.102977.
3
Cardiotoxicity as important differential diagnosis for reduced myocardial blood flow during Rubidium cardiac PET/CT : Cardiotoxicity in Rubidium PET/CT.铷心肌PET/CT检查时心肌血流减少的重要鉴别诊断——心脏毒性：铷PET/CT中的心脏毒性
Int J Cardiovasc Imaging. 2025 Apr;41(4):817-819. doi: 10.1007/s10554-024-03315-4. Epub 2025 Jan 8.
4
Hazard-based risk grouping effectively stratifying breast cancer patients in post-irradiation long-term heart diseases: a population-based cohort study.基于风险的分组有效分层乳腺癌患者放疗后长期心脏病：一项基于人群的队列研究。
Front Cardiovasc Med. 2023 Apr 27;10:980101. doi: 10.3389/fcvm.2023.980101. eCollection 2023.
5
Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives.临床实践中癌症治疗相关的心血管并发症：当前观点
J Clin Med. 2021 Apr 13;10(8):1647. doi: 10.3390/jcm10081647.
6
The Predictive Value of 2D Myocardial Strain for Epirubicin-Induced Cardiotoxicity.二维心肌应变对表柔比星所致心脏毒性的预测价值
J Oncol. 2020 Nov 30;2020:5706561. doi: 10.1155/2020/5706561. eCollection 2020.

本文引用的文献

1
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.免疫检查点抑制剂治疗患者的心肌炎。
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764. doi: 10.1016/j.jacc.2018.02.037. Epub 2018 Mar 19.
2
Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial.表阿霉素对乳腺癌女性心力衰竭发生率的长期影响：来自一项随机临床试验的观察。
Eur J Heart Fail. 2018 Oct;20(10):1447-1453. doi: 10.1002/ejhf.1168. Epub 2018 Mar 1.
3
Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?蒽环类药物治疗的心脏毒性作用：有哪些证据和潜在危害？
Lancet Oncol. 2017 Aug;18(8):e445-e456. doi: 10.1016/S1470-2045(17)30535-1. Epub 2017 Jul 26.
4
A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer.基于人群的早期乳腺癌患者心血管死亡率研究。
JAMA Cardiol. 2017 Jan 1;2(1):88-93. doi: 10.1001/jamacardio.2016.3841.
5
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).2016年欧洲心脏病学会（ESC）实践指南委员会主持制定的关于癌症治疗与心血管毒性的立场文件：欧洲心脏病学会（ESC）癌症治疗与心血管毒性特别工作组。
Eur J Heart Fail. 2017 Jan;19(1):9-42. doi: 10.1002/ejhf.654. Epub 2016 Aug 27.
6
Cancer treatment and survivorship statistics, 2016.癌症治疗和生存统计，2016 年。
CA Cancer J Clin. 2016 Jul;66(4):271-89. doi: 10.3322/caac.21349. Epub 2016 Jun 2.
7
Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?肿瘤学临床试验中的心血管风险评估：集中事件判定是否有作用？
Eur J Heart Fail. 2016 Feb;18(2):128-32. doi: 10.1002/ejhf.457. Epub 2015 Dec 13.
8
Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level.癌症患者及癌症幸存者的心血管健康：迈向新高度的路线图。
J Am Coll Cardiol. 2015 Jun 30;65(25):2739-46. doi: 10.1016/j.jacc.2015.04.059.
9
Validity of heart failure diagnoses in administrative databases: a systematic review and meta-analysis.行政数据库中心力衰竭诊断的有效性：一项系统评价与荟萃分析。
PLoS One. 2014 Aug 15;9(8):e104519. doi: 10.1371/journal.pone.0104519. eCollection 2014.
10
Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer.乳腺癌辅助表柔比星化疗后的长期心脏功能。
Acta Oncol. 2012 Nov;51(8):1054-61. doi: 10.3109/0284186X.2012.702920. Epub 2012 Aug 22.